Skip to content

RXRX

Recursion Pharmaceuticals, Inc.

NASDAQ · Healthcare · Biotechnology · US

$3.63
+5.52%
Ask drillr
0
Insider buys (3m)
4
Insider sells (3m)
-$368.8K
Net value (3m)
+9.0%
Price return (3m)
Form 4 filings
DateInsiderActivitySharesPrice
Sep 2, 2026Borgeson Blake · directorSale30,000$3.34
Aug 18, 2026Khan Najat · director, officer: CEO and PresidentF-InKind80,498$3.16
Aug 18, 2026Taylor Ben R · officer: Chief Financial OfficerF-InKind25,018$3.16
Aug 18, 2026Hallett David · officer: Chief Scientific OfficerF-InKind26,657$3.16
Aug 6, 2026Borgeson Blake · directorSale30,000$3.25
Jul 9, 2026Borgeson Blake · directorSale40,000$3.96
Jul 2, 2026Dar Zavain · directorA-Award5,109$0.00
Jul 2, 2026Li Dean Y · directorA-Award3,747$0.00
Jun 22, 2026Dar Zavain · directorA-Award88,424$0.00
Jun 22, 2026Bumpus Namandje · directorA-Award88,424$0.00
Jun 22, 2026Bumpus Namandje · directorSale3,963$3.18
Jun 22, 2026Borgeson Blake · directorA-Award88,424$0.00
Jun 22, 2026Li Dean Y · directorA-Award88,424$0.00
Jun 22, 2026Michor Franziska · directorA-Award88,424$0.00
Jun 22, 2026Sun Elaine D · directorA-Award88,424$0.00
Jun 22, 2026HERSHBERG ROBERT · directorA-Award88,424$0.00
Jun 17, 2026Taylor Ben R · officer: Chief Financial OfficerF-InKind5,396$3.15
Jun 5, 2026Khan Najat · director, officer: CEO and PresidentSale23,588$3.58
Jun 5, 2026Gibson Christopher · directorSale40,000$3.62
Jun 4, 2026Borgeson Blake · directorSale30,000$3.68
Jun 4, 2026Bumpus Namandje · directorSale4,386$3.54
May 27, 2026Gibson Christopher · directorSale40,000$3.08
May 19, 2026Hallett David · officer: Chief Scientific OfficerF-InKind26,657$3.04
May 19, 2026Gibson Christopher · directorF-InKind22,821$3.04
May 19, 2026Khan Najat · director, officer: CEO and PresidentF-InKind62,701$3.04
May 19, 2026Taylor Ben R · officer: Chief Financial OfficerF-InKind25,018$3.04
May 8, 2026Gibson Christopher · directorSale40,000$3.37
May 7, 2026Borgeson Blake · directorSale30,000$3.52
Apr 24, 2026Gibson Christopher · directorSale40,000$3.61
Apr 8, 2026Taylor Ben R · officer: Chief Financial OfficerF-InKind48,028$3.11
Institutional positioning

13F filings over the trailing two quarters

New 117Increased 267Reduced 189Sold out 45
FilerActionSharesFiled
BlackRock, Inc.Increased50,304,691Aug 7, 2026
BLACKROCK, INC.Increased43,192,306May 13, 2026
ARK Investment Management LLCIncreased41,337,632Aug 14, 2026
ARK INVESTMENT MANAGEMENT LLCIncreased40,212,769May 12, 2026
STATE STREET CORPIncreased34,706,130Aug 7, 2026
VANGUARD PORTFOLIO MANAGEMENT LLCIncreased31,131,599Aug 13, 2026
STATE STREET CORPIncreased28,490,638May 15, 2026
BAILLIE GIFFORD & COReduced23,675,407May 8, 2026
BAILLIE GIFFORD & COReduced23,487,907Aug 6, 2026
VANGUARD CAPITAL MANAGEMENT LLCIncreased22,765,940Aug 13, 2026
VANGUARD PORTFOLIO MANAGEMENT LLCNew Position22,759,100May 8, 2026
VANGUARD CAPITAL MANAGEMENT LLCNew Position22,244,387May 15, 2026
GEODE CAPITAL MANAGEMENT, LLCIncreased13,819,135Aug 12, 2026
SOFTBANK GROUP CORP.Unchanged13,636,515Aug 14, 2026
SOFTBANK GROUP CORP.Unchanged13,636,515May 15, 2026

Insider activity from SEC Form 4; institutional positioning from 13F filings · Latest filing Sep 2, 2026